Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2016

Open Access 01-06-2016 | Commentary

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects

Published in: Diabetologia | Issue 6/2016

Login to get access

Excerpt

An increase in the prevalence of obesity and the metabolic syndrome as a result of changes in eating habits, both quantitative (over-eating) and qualitative (e.g. high fructose consumption), and a lack of exercise contribute to fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is a clinical histological spectrum ranging from steatosis to non-alcoholic steatohepatitis (NASH) and affects more than 30% of the general population [1]. …
Literature
1.
Browning JD, Szczepaniak LS, Dobbins R et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387–1395CrossRefPubMed
2.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. doi:10.​1007/​s00125-016-3902-y
3.
Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005–2023CrossRefPubMed
4.
Roeb E, Steffen HM, Bantel H et al (2015) S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 53:668–723 [Article in German]CrossRefPubMed
5.
Rinella ME, Lominadze Z, Loomba R et al (2016) Practice patterns in NAFLD and NASH: real life differs from published guideline. Ther Adv Gastroenterol 9:4–12CrossRef
6.
Frühbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM, Executive Committee of the European Association for the Study of Obesity (2013) Obesity: the gateway to ill health—an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts 6:117–120CrossRefPubMed
7.
Metadata
Title
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects
Publication date
01-06-2016
Published in
Diabetologia / Issue 6/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3941-4

Other articles of this Issue 6/2016

Diabetologia 6/2016 Go to the issue

Article

PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes

Commentary

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?

Mini-Review

Diagnosis of non-alcoholic fatty liver disease (NAFLD)

Article

O-GlcNAcase deficiency suppresses skeletal myogenesis and insulin sensitivity in mice through the modulation of mitochondrial homeostasis

Article

Extreme obesity induces massive beta cell expansion in mice through self-renewal and does not alter the beta cell lineage

Up front

Up front June 2016

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits